Description186Re-Rhenium Etidronate (commonly referred to as 186Re-HEDP, hydroxyethylidene diphosphonate, or 186Re-Etidronate) is a radiopharmaceutical developed by Mallinckrodt for palliating bone pain caused by metastatic bone cancer. This innovative formulation was initially approved and launched in Switzerland and Greece. However, despite its potential, the New Drug Application (NDA) submitted to the… Continue Reading…
Description 177Lu-Oxodotreotide (also known as 177Lu-Lutathera®, 177Lu-DOTATATE, and Lutetium-177 dotatate) is a somatostatin analogue developed for the treatment of neuroendocrine tumors (NETs). It was the first 177Lu-labeled molecule to receive marketing authorization. The drug was originally developed by Biosynthema, which was acquired by Advanced Accelerator Applications (AAA) in 2010. The… Continue Reading…
What is 169Er-Erbium Citrate? 169Er-Erbium Citrate is a specialized radiopharmaceutical therapy designed for isotopic radiation synovectomy, particularly targeting small joints such as those in the hands and feet. This treatment leverages the therapeutic benefits of radioactive isotopes to alleviate symptoms of joint-related conditions. Clinical Applications of 169Er-Erbium Citrate This therapy… Continue Reading…
Overview166Ho-Chitosan, also known as DW166-HC, is an innovative radiopharmaceutical drug designed for targeted cancer therapy. Commercially available under the brand name Milican in South Korea, it was developed by Dong Wha Pharmaceuticals and launched in August 2001. This therapeutic agent offers a novel approach for treating hepatocellular carcinoma (HCC), leveraging… Continue Reading…
Description 166Ho-QuiremSpheres (also known as 166Ho-PLLA-MS) is a medical device developed at the University Medical Center Utrecht in the Netherlands. The product consists of microparticles loaded with the radioactive isotope Holmium-166. These microparticles are created by activating 165Ho pre-loaded poly-L-lactic acid (PLLA) particles with neutron flux in a reactor, using… Continue Reading…
Description133Xe-Xenon serves as a diagnostic radiopharmaceutical. It is primarily used as a gas (5% diluted in carbon dioxide) for evaluating pulmonary function and lung imaging. Additionally, a saline solution form allows its use in cerebral blood flow assessment. Clinical ApplicationsThe gas form of 133Xe-Xenon helps in lung ventilation imaging. Typical… Continue Reading…
Manufacturer and Development131I-Weimeisheng, also known as 131I-Tumor Necrosis Therapy monoclonal antibody (mAb) injection, is a radiolabeled chimeric antibody. It was originally developed at the University of Southern California and later commercialized in China by Shanghai Meien Biotechnology and the China Isotope & Radiation Corporation (CIRC). Classified as a ‘me-too plus’… Continue Reading…